« Back to Record
Citation APA

De Greve, J., Berchem, G., Colinet, B., Galdermans, D., Bosquée, L., Vermeij, J., Dewaele, A., Geers, C., Schallier, D., Teugels, E., Van Meerbeeck, J. P. A. M. J., Vansteenkiste, J., Decoster, L., Meert, A.-P., Vuylsteke, P., Focan, C., Canon, J.-L., & Humblet, Y. (2016). Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). PloS one, 11(3), e0147599. doi:10.1371/journal.pone.0147599


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/259004

De Greve, J., Berchem, G., Colinet, B., Galdermans, D., Bosquée, L., Vermeij, J., Dewaele, A., Geers, C., Schallier, D., Teugels, E., Van Meerbeeck, J. P. A. M. J., Vansteenkiste, J., Decoster, L., Meert, A.-P., Vuylsteke, P., Focan, C., Canon, J.-L., & Humblet, Y. (2016). Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). PloS one, 11(3), e0147599. doi:10.1371/journal.pone.0147599